GT Biopharma, Inc. Balance Sheet
GTBP|8 years of annual SEC 10-K data (FY2011-FY2020)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 8 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.3M | $19.0K | $855.0K | $43.0K | $43.0K | $123.0K | $92.0K | $54.0K |
| Accounts Receivable | - | - | - | - | - | $40.0K | - | - |
| Inventory | - | - | - | - | - | $42.0K | $59.0K | $12.0K |
| Current Assets | $5.7M | $576.0K | $49.0K | $882.0K | $882.0K | $125.0K | $202.0K | $104.0K |
| PP&E (Net) | - | $6.0K | $5.0K | $6.0K | $6.0K | - | - | - |
| Total Assets | - | $254.4M | $54.0K | $888.0K | $888.0K | $147.0K | $226.0K | $129.0K |
| Current Liabilities | $35.1M | $2.7M | $61.2M | $29.8M | $29.8M | $6.4M | $6.6M | $5.2M |
| Shareholders' Equity | -$19.3M | $251.7M | -$61.8M | -$29.6M | -$29.6M | -$6.3M | -$6.3M | -$5.1M |